The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel
Abstract Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for trea...
Saved in:
Main Authors: | Joshua Burshtein (Author), Milaan Shah (Author), Danny Zakria (Author), Benjamin Lockshin (Author), Jeff Crowley (Author), Joseph F. Merola (Author), Ken Gordon (Author), Mona Shahriari (Author), Neil J. Korman (Author), Raj Chovatiya (Author), Robert Kalb (Author), Mark Lebwohl (Author) |
---|---|
Format: | Book |
Published: |
Adis, Springer Healthcare,
2024-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Expert panel consensus recommendations for diagnosis and treatment of secondary osteoporosis in children
by: Rocío Galindo-Zavala, et al.
Published: (2020) -
Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis
by: Lyn Guenther, et al.
Published: (2024) -
Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
by: Yuqian Wang, et al.
Published: (2023) -
Review of bimekizumab in the treatment of psoriasis
by: Sindhuja Koppu, et al.
Published: (2022) -
Bimekizumab Efficacy and Safety in Japanese Patients with Plaque Psoriasis in BE VIVID: A Phase 3, Ustekinumab and Placebo-Controlled Study
by: Akihiko Asahina, et al.
Published: (2023)